$ELAB
PMGC Holdings Inc. Stock $elab

$elab Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024027576 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$614.6K	$698.6K	$1.713M
YoY Change	338.97%		122.42%
Cost Of Revenue	$168.9K	$236.9K	$578.0K
YoY Change	322.28%		80.63%
Gross Profit	$445.7K	$461.7K	$1.135M
YoY Change	345.65%		152.13%
Gross Profit Margin	72.52%	66.09%	66.25%
Selling, General & Admin	$1.272M	$1.411M	$4.458M
YoY Change	47.87%		122.91%
% of Gross Profit	285.35%	305.63%	392.93%
Research & Development	$103.2K	$122.5K	$426.2K
YoY Change	28.99%		85.32%
% of Gross Profit	23.16%	26.53%	37.57%
Depreciation & Amortization	$21.19K	$2.910K	$11.65K
YoY Change		-70.9%	16.5%
% of Gross Profit	4.75%	0.63%	1.03%
Operating Expenses	$2.129M	$1.536M	$4.895M
YoY Change	124.12%		118.51%
Operating Profit	-$1.683M	-$1.074M	-$3.760M
YoY Change	98.05%		110.06%
Interest Expense	$251.0K	$366.5K	-$91.36K
YoY Change	-209.11%		813.6%
% of Operating Profit
Other Income/Expense, Net	$34.72K	$32.19K	-$3.766M
YoY Change			110.28%
Pretax Income	-$1.397M	-$1.158M	-$4.302M
YoY Change	29.38%		138.97%
Income Tax
% Of Pretax Income
Net Earnings	-$1.397M	-$1.158M	-$4.302M
YoY Change	29.38%		138.97%
Net Earnings / Revenue	-227.36%	-165.75%	-251.17%
Basic Earnings Per Share	-$0.08		-$0.40
Diluted Earnings Per Share	-$0.08	-$0.07	-$0.25
COMMON SHARES
Basic Shares Outstanding	17.33M shares	17.33M shares	10.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$943.8K	$3.327M	$3.327M
YoY Change			189.29%
Cash & Equivalents	$943.8K	$3.327M
Short-Term Investments
Other Short-Term Assets	$1.198M	$1.061M	$1.061M
YoY Change			607.18%
Inventory	$945.1K	$495.7K	$495.7K
Prepaid Expenses
Receivables	$48.59K	$33.09K	$33.09K
Other Receivables	$5.620K	$3.070K	$3.070K
Total Short-Term Assets	$3.141M	$4.919M	$4.919M
YoY Change		-99.68%	217.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.00K	$259.7K	$259.7K
YoY Change		-99.51%	-21.3%
Goodwill
YoY Change
Intangibles	$843.5K	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.77K	$10.77K	$10.77K
YoY Change			7.7%
Total Long-Term Assets	$1.086M	$270.5K	$270.5K
YoY Change		-99.92%	-20.45%
TOTAL ASSETS
Total Short-Term Assets	$3.141M	$4.919M	$4.919M
Total Long-Term Assets	$1.086M	$270.5K	$270.5K
Total Assets	$4.227M	$5.190M	$5.190M
YoY Change		-99.73%	174.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$395.2K	$596.2K	$596.2K
YoY Change			170.98%
Accrued Expenses	$133.6K	$218.2K	$218.2K
YoY Change			55.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.222M	$1.297M	$1.297M
YoY Change		-99.78%	119.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$518.1K	$65.49K	$65.49K
YoY Change			-61.48%
Total Long-Term Liabilities	$518.1K	$65.49K	$65.49K
YoY Change			-61.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.222M	$1.297M	$1.297M
Total Long-Term Liabilities	$518.1K	$65.49K	$65.49K
Total Liabilities	$1.740M	$1.363M	$1.363M
YoY Change		-99.82%	79.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.421M	-$7.024M
YoY Change		-99.74%
Common Stock	$10.91M	$1.733K
YoY Change	-70.92%	-99.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.486M	$3.827M	$3.827M
YoY Change
Total Liabilities & Shareholders Equity	$4.227M	$5.190M	$5.190M
YoY Change		-99.73%	174.6%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.397M	-$1.158M	-$4.302M
YoY Change	29.38%		138.97%
Depreciation, Depletion And Amortization	$21.19K	$2.910K	$11.65K
YoY Change		-70.9%	16.5%
Cash From Operating Activities	-$2.324M	-$2.388M	-$4.557M
YoY Change	162.46%	117.1%	186.59%
INVESTING ACTIVITIES
Capital Expenditures	$9.160K	$0.00	$11.19K
YoY Change	-18.15%	-100.0%	-72.03%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$59.16K	$0.00	-$11.19K
YoY Change	428.64%	-100.0%	-62.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.501M
YoY Change			244.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		5.238M	6.739M
YoY Change		177.13%	185.55%
NET CHANGE
Cash From Operating Activities	-$2.324M	-2.388M	-4.557M
Cash From Investing Activities	-$59.16K	0.000	-11.19K
Cash From Financing Activities		5.238M	6.739M
Net Change In Cash	-$2.383M	2.850M	2.171M
YoY Change	2085.17%	274.95%	193.36%
FREE CASH FLOW
Cash From Operating Activities	-$2.324M	-$2.388M	-$4.557M
Capital Expenditures	$9.160K	$0.00	$11.19K
Free Cash Flow	-$2.333M	-$2.388M	-$4.568M
YoY Change	160.2%	111.34%	180.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41875
CY2023	dei	Entity Registrant Name EntityRegistrantName	ELEVAI LABS INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1399981
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Jordan Plews
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	120 Newport Center Drive
CY2023	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 250
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
CY2023	dei	City Area Code CityAreaCode	(866)
CY2023	dei	Local Phone Number LocalPhoneNumber	794-4940
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ELAB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17329615	shares
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4916092	usd
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	6706
CY2023	dei	Auditor Name AuditorName	TPS Thayer, LLC
CY2023	dei	Auditor Location AuditorLocation	Sugar Land, Texas
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1154901	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12854	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	153422	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	230145	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4919444	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1551322	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53119	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53535	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	206582	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	276553	usd
CY2023Q4	us-gaap	Assets Assets	5189918	usd
CY2022Q4	us-gaap	Assets Assets	1892183	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	669375	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	244704	usd
CY2023Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	36693	usd
CY2022Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	10172	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	77127	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	154325	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	145000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110616	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	369158	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	68455	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1297353	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	588272	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65489	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	172601	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1362842	usd
CY2022Q4	us-gaap	Liabilities Liabilities	760873	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9568475	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9568475	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1733	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	957	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10849031	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3852044	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	202	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	111	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2722373	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1131310	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5189918	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1892183	usd
CY2023	us-gaap	Revenues Revenues	1712595	usd
CY2022	us-gaap	Revenues Revenues	766277	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	578015	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	318968	usd
CY2023	us-gaap	Gross Profit GrossProfit	1134580	usd
CY2022	us-gaap	Gross Profit GrossProfit	447309	usd
CY2023	us-gaap	Depreciation Nonproduction DepreciationNonproduction	10295	usd
CY2022	us-gaap	Depreciation Nonproduction DepreciationNonproduction	5034	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	660291	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	192863	usd
CY2023	us-gaap	Management Fee Expense ManagementFeeExpense	459498	usd
CY2022	us-gaap	Management Fee Expense ManagementFeeExpense	324395	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2329067	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1019708	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	579111	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	192409	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-91009	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-74003	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	426243	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	228747	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6130	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2749	usd
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	339147	usd
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	198442	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4900791	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2238350	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3766211	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1791041	usd
CY2023	elab	Listing Expense ListingExpense	450079	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	71266	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12754	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	5564	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	7702	usd
CY2023	us-gaap	Interest Expense InterestExpense	19525	usd
CY2022	us-gaap	Interest Expense InterestExpense	2629	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1546	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4301517	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1800268	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	91	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-91	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4301426	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1800359	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.4
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.189
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10745938	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9528863	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	450628	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2186421	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-33132	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	130883	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	171869	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1800268	usd
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-91	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1131310	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1131310	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1463586	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	37500	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6000000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-991632	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	487738	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4301517	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	91	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4301517	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1800268	usd
CY2023	us-gaap	Depreciation Depreciation	11649	usd
CY2022	us-gaap	Depreciation Depreciation	6512	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	2614	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	487738	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	171869	usd
CY2023	us-gaap	Straight Line Rent StraightLineRent	2757	usd
CY2022	us-gaap	Straight Line Rent StraightLineRent	-6664	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1546	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	71266	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12754	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23218	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11547	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	907343	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	102055	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	265522	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	69328	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	466891	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	65191	usd
CY2023	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	26521	usd
CY2022	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	10172	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-120519	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	120000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4556811	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1585876	usd
CY2023	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	11191	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	35527	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3500	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11191	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32027	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37500	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25000	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	2153289	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1463585	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6000000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	762195	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	183970	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6738890	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2362259	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1062	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1313	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2171950	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	743043	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1154901	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411858	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1154901	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	14397	usd
CY2023	elab	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	3527701	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	186584	usd
CY2023	elab	Derivative Liability Broker Warrants Included In Share Issuance Cost For Ipo DerivativeLiabilityBrokerWarrantsIncludedInShareIssuanceCostForIPO	229437	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Organization and nature of operations</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiary, Elevai Research Inc, are collectively referred to in these consolidated financial statements as “the Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products.</span></p>
CY2020Q2	elab	Ownership Percentage By Parent OwnershipPercentageByParent	1	pure
CY2023Q4	elab	Net Working Capital NetWorkingCapital	3622091	usd
CY2022Q4	elab	Net Working Capital NetWorkingCapital	963050	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2722373	usd
CY2023	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	4301517	usd
CY2022	us-gaap	Net Income Loss Allocated To Limited Partners NetIncomeLossAllocatedToLimitedPartners	1800268	usd
CY2023	us-gaap	Increase Decrease In Insurance Assets IncreaseDecreaseInInsuranceAssets	4556811	usd
CY2022	us-gaap	Increase Decrease In Insurance Assets IncreaseDecreaseInInsuranceAssets	1585876	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.</span></p>
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1712595	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	578015	usd
CY2023	us-gaap	Gross Profit GrossProfit	1134580	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	4900791	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-535306	usd
CY2023	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	4301517	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	4919444	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	270474	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	5189918	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1297353	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	65489	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1362842	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3827076	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1712595	usd
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer. Revenue is measured based on the consideration the Company expects to receive in exchange for those products. In instances where financial acceptance of the product is specified by the customer, revenue is deferred until all acceptance criteria have been met. Revenues are recognized under ASC 606, “Revenue from Contracts with Customers,” in a manner that reasonably reflects the delivery of its products and services to customers in return for expected consideration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company generates revenue through the sale of skincare products. Revenue from the sale of skincare products are recognized at the point in time when the Company considered revenue realized or realizable and earned, which is typically when all of the five following criteria are met: (1) the contract with the customer is identifiable (i.e. when a sales transaction has been entered into between the Company and the customer), (2) the performance obligation in the contract is identifiable (i.e. the customer has ordered a known quantity of product to be delivered), (3) the transaction price is determinable (i.e. the customer has agreed to the Company’s price for the products ordered), (4) the Company is able to allocate the transaction price to the performance obligations in the contract, and (5) the performance obligations have been satisfied, which is typically upon delivery of the product to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transaction prices for performance obligations are explicitly outlined in relevant agreements; therefore, the Company does not believe that significant judgements are required with respect to the determination of the transaction price, including any variable consideration identified.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company is responsible for providing the products to customers. As a result, the Company is considered the Principal when providing products to customers. As the Company collects payment at the time of the customer order, its contracts do not have a significant financing component. Customers are entitled to replacement or full refund of any damaged or defective product, after the return of the damaged or defective product to the Company. There were no significant returns or refunds during the year ended December 31, 2023 and 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash, receivables and refundable deposits are the only financial instruments that are potentially subject to credit risk. The Company places its cash in what it believes to be credit-worthy financial institutions. Receivables relate to sales taxes paid that is reimbursable from the Canadian government and timing differences on receiving proceeds from sales transactions processed through customer credit cards. Refundable deposits relate to the Company’s security deposit on lease agreements.</span></p>
CY2023Q4	us-gaap	Cash Cash	3326851	usd
CY2023Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities	369158	usd
CY2023Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	3696009	usd
CY2022Q4	us-gaap	Cash Cash	1154901	usd
CY2022Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities	68455	usd
CY2022Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	1223356	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	487738	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	171869	usd
CY2023	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	476905	usd
CY2022	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	10833	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	164907	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	6962	usd
CY2023	elab	Trade Receivable TradeReceivable	33089	usd
CY2022	elab	Trade Receivable TradeReceivable	4180	usd
CY2023	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	3072	usd
CY2022	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	8674	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12854	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	957645	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	89819	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	113893	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	24376	usd
CY2022Q4	us-gaap	Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Net DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet	50000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	1071538	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	164195	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	153422	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	230145	usd
CY2023Q4	us-gaap	General And Administrative Costs In Inventory Amount Remaining GeneralAndAdministrativeCostsInInventoryAmountRemaining	363082	usd
CY2022Q4	us-gaap	General And Administrative Costs In Inventory Amount Remaining GeneralAndAdministrativeCostsInInventoryAmountRemaining	251580	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	124376	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	36501	usd
CY2021Q4	elab	Equipment Furnitureand Fixtures Computers Total Cost EquipmentFurnitureandFixturesComputersTotalCost	32482	usd
CY2022	elab	Equipment Furnitureand Fixtures Computers Additions EquipmentFurnitureandFixturesComputersAdditions	35527	usd
CY2022	elab	Equipment Furnitureand Fixtures Computers Disposal EquipmentFurnitureandFixturesComputersDisposal	6188	usd
CY2022	elab	Equipment Furnitureand Fixtures Computers Foreign Currency Translation EquipmentFurnitureandFixturesComputersForeignCurrencyTranslation	181	usd
CY2022Q4	elab	Equipment Furnitureand Fixtures Computers Total Cost EquipmentFurnitureandFixturesComputersTotalCost	61640	usd
CY2023	elab	Equipment Furnitureand Fixtures Computers Additions EquipmentFurnitureandFixturesComputersAdditions	11191	usd
CY2023	elab	Equipment Furnitureand Fixtures Computers Foreign Currency Translation EquipmentFurnitureandFixturesComputersForeignCurrencyTranslation	-61	usd
CY2023Q4	elab	Equipment Furnitureand Fixtures Computers Total Cost EquipmentFurnitureandFixturesComputersTotalCost	72892	usd
CY2021Q4	elab	Equipment Furnitureand Fixtures Computers Accumulated Depreciation EquipmentFurnitureandFixturesComputersAccumulatedDepreciation	2757	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6512	usd
CY2022	elab	Disposal Disposal	1142	usd
CY2022	elab	Foreign Currency Translation Accumulated Depreciation ForeignCurrencyTranslationAccumulatedDepreciation	22	usd
CY2022Q4	elab	Equipment Furnitureand Fixtures Computers Accumulated Depreciation EquipmentFurnitureandFixturesComputersAccumulatedDepreciation	8105	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	11649	usd
CY2023	elab	Foreign Currency Translation Accumulated Depreciation ForeignCurrencyTranslationAccumulatedDepreciation	-19	usd
CY2023Q4	elab	Equipment Furnitureand Fixtures Computers Accumulated Depreciation EquipmentFurnitureandFixturesComputersAccumulatedDepreciation	19773	usd
CY2021Q4	elab	Equipment Furnitureand Fixtures Computers Net Book Value EquipmentFurnitureandFixturesComputersNetBookValue	53535	usd
CY2023Q4	elab	Equipment Furnitureand Fixtures Computers Net Book Value EquipmentFurnitureandFixturesComputersNetBookValue	53119	usd
CY2023Q4	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	1354	usd
CY2022Q4	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	1478	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	47986	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	142741	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	73802	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	161721	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67384	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	229105	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18616	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	210489	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	145000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65489	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	13476.75	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115	pure
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.08	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	596147	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	210840	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	73228	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	33864	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	669375	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	244704	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	183970	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	183970	usd
CY2023Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.8
CY2023	elab	Warrant Percentage WarrantPercentage	1	pure
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	2.01
CY2023Q4	elab	Preferred Stock Convertible Conversion Price Percentage PreferredStockConvertibleConversionPricePercentage	1.50	pure
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.01
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2028-11-21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M15D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M9D
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	231828	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2027-04-27
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	62500	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.6
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37500	usd
CY2023Q1	elab	Purchase Of Common Stock Warrants PurchaseOfCommonStockWarrants	250000	shares
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	750000	usd
CY2023Q3	elab	Purchase Of Common Stock Warrants PurchaseOfCommonStockWarrants	99998	shares
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000000	usd
CY2023Q4	elab	Class Of Underwriter Warrants Issued ClassOfUnderwriterWarrantsIssued	75000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4
CY2023Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	762194	usd
CY2023Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	730000	usd
CY2023Q4	us-gaap	Other Expenses OtherExpenses	32194	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y9M21D
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1734188	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1734188	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10767	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	222500	shares
CY2023Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	80000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q2	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	584787	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	80000	shares
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1500	shares
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3940	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	45000	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.6
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11617	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	262000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1.34
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	317652	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	105000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115868	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0386	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0407	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M2D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y6M29D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	487738	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	171869	usd
CY2023Q4	elab	Percentage Of Authority Control PercentageOfAuthorityControl	0.10	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	800000	shares
CY2021Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.6
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	203972	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	160000	shares
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5
CY2023Q2	us-gaap	Stock Issued1 StockIssued1	420521	usd
CY2023Q2	elab	Stock Option Cancelled And Reissued StockOptionCancelledAndReissued	80000	shares
CY2021Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.6
CY2021Q3	us-gaap	Stock Issued1 StockIssued1	51014	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	137500	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	62500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	250000	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.22
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	357349	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	56724	usd
CY2023	elab	Grant Date Fair Value Of Stock Options GrantDateFairValueOfStockOptions	997053	usd
CY2023Q4	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22455	usd
CY2022Q4	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22705	usd
CY2023	us-gaap	Legal Fees LegalFees	4272	usd
CY2022	us-gaap	Legal Fees LegalFees	2971	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4301517	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1800268	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2787	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2787	pure
CY2023	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	1198833	usd
CY2022	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	501735	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	135947	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47906	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	19864	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3555	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-2168	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	3602	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1031	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1292	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1044159	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	445380	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4168622	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1615645	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1710000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	662000	usd
CY2023	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	12500	cad
CY2023	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	9225	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	158603	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1712595	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.0926	pure
CY2023	elab	Customer Representing Revenue CustomerRepresentingRevenue	234800	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	344018	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	elab	Listing Expense ListingExpense		usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.189
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.400
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	elab	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1		usd
CY2022	elab	Derivative Liability Broker Warrants Included In Share Issuance Cost For Ipo DerivativeLiabilityBrokerWarrantsIncludedInShareIssuanceCostForIPO		usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2023Q4	us-gaap	Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Net DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet		usd
CY2023Q4	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2022Q4	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023	elab	Equipment Furnitureand Fixtures Computers Disposal EquipmentFurnitureandFixturesComputersDisposal		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001840563

Files In Submission

Name	View Source	Status
0001213900-24-027576-index-headers.html	Edgar Link	pending
0001213900-24-027576-index.html	Edgar Link	pending
0001213900-24-027576.txt	Edgar Link	pending
0001213900-24-027576-xbrl.zip	Edgar Link	pending
ea0202347-10k_elevai.htm	Edgar Link	pending
ea020234701ex10-10_elevai.htm	Edgar Link	pending
ea020234701ex10-8_elevai.htm	Edgar Link	pending
ea020234701ex10-9_elevai.htm	Edgar Link	pending
ea020234701ex19_elevai.htm	Edgar Link	pending
ea020234701ex31-1_elevai.htm	Edgar Link	pending
ea020234701ex31-2_elevai.htm	Edgar Link	pending
ea020234701ex32-1_elevai.htm	Edgar Link	pending
ea020234701ex4-2_elevai.htm	Edgar Link	pending
ea020234701ex97_elevai.htm	Edgar Link	pending
elab-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
elab-20231231_cal.xml	Edgar Link	unprocessable
elab-20231231_def.xml	Edgar Link	unprocessable
elab-20231231_lab.xml	Edgar Link	unprocessable
elab-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ea0202347-10k_elevai_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELAB
PMGC Holdings Inc. Stock $elab

2024 Q1 Form 10-K Financial Statement

#000121390024027576 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB PMGC Holdings Inc. Stock $elab

2024 Q1 Form 10-K Financial Statement

#000121390024027576 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB
PMGC Holdings Inc. Stock $elab